The Parathyroid Glands, Hypercalcemia, and Hypocalcemia

Goldman's Cecil Medicine: Twenty Fourth Edition

Volumn 2, Issue , 2012, Pages 1591-1601

  Wysolmerski, John J ^a   Insogna, Karl L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893906776     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1604-7.00253-0     Document Type: Chapter

References (12)

1. Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009, 94:4860-4867.
2. Augustine MM, Bravo PE, Zeiger MA Treatment of primary hyperparathyroidism. Endocr Pract 2011, 17:75-82. Review including imaging for preoperative localization and the use of minimally invasive and endoscopic-, video-, and robot-assisted parathyroidectomy.
3. Bilezikian JP, Khan AA, Potts JT Guidelines for the management of asymptomatic primary hyperparathyroidism; summary statement from the third international workshop. J Clin Endocrinol Metab 2009, 94:335-339. Summary of the latest expert recommendations for the management of hyperparathyroidism.
4. Felger EA, Kandil E Primary hyperparathyroidism. Otolaryngol Clin North Am 2010, 43:417-432. Review emphasizing the role of surgery, including preoperative localization and intraoperative parathyroid hormone measurement.
5. Sankaran S, Gamble G, Bolland M, et al. Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab 2010, 95:1653-1662. Surgical and antiresorptive treatments increase bone mineral density in mild primary hyperparathyroidism to a similar degree.
6. Sharretts JM, Kebebew E, Simonds WF Parathyroid cancer. Semin Oncol 2010, 37:580-590. This uncommon malignancy is a rare and serious cause of primary hyperparathyroidism.
7. Bastepe M The GNAS locus and pseudohypoparathyroidism. Adv Exp Med Biol 2008, 626:27-40. In-depth discussion of alterations in the GNAS gene that cause PTH resistance.
8. Brown EM Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism. Endocrinol Metab Clin North Am 2009, 437-445. Recent advances in novel parathyroid autoantigens and their implications for treatment.
9. Liamis G, Haralampos JM, Elisaf M A review of drug-induced hypocalcemia. J Bone Min Metab 2009, 27:635-642. Useful summary of drugs commonly used in clinical practice that can cause hypocalcemia.
10. Mundy GR, Edwards JR PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol 2008, 19:672-675. Discussion of PTHrP's role in the pathophysiology of hypercalcemia and bone metastases.
11. Rubin MR, Bilezikian JP, McMahon DJ, et al. The Natural History of Primary Hyperparathyroidism with or without Surgery after 15 years. J Clin Endocrinol Metab 2008, 93:3462-3470. Important update showing that, without surgery, primary hyperparathyroidism progresses in one third of individuals.
12. Strippoli GF, Tong A, Palmer SC, et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev. 2006;4:CD006254. Treatment improves biochemical parameters, but patient-based benefits have not yet been demonstrated.